Results 71 to 80 of about 82,941 (302)

GHRH-antagonists in TNBC

Oncotarget, 2015
“Triple negative breast cancer” (TNBC) represents a subgroup of breast cancers (BC), which do not express receptors for either estrogen or progesterone and which do not overexpress HER-2 receptors. Although this subgroup is characterized by immunohistochemistry, there is a seventy percent overlap with basal-like breast cancers, defined by gene ...
openaire   +1 more source

Bursts of Chromosome Changes Drive TNBC [PDF]

Cancer Discovery, 2016
Abstract A recent study suggests that complex genomic rearrangements in triple-negative breast cancer cells occur through a “Big Bang” model—early, short bursts of copy number aberrations, rather than progressive accumulation over time.
openaire   +2 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

MicroRNA-223 is Associated with Resistance Towards Platinum-based Chemotherapy and Worse Prognosis in Indonesian Triple-negative Breast Cancer Patients

Breast Cancer: Targets and Therapy, 2021
Ibnu Purwanto,1 Didik Setyo Heriyanto,2 Irianiwati Widodo,2 Mohammad Hakimi,3 Mardiah Suci Hardianti,1 Teguh Aryandono,4 Sofia Mubarika Haryana5 1Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public ...
Purwanto I, Heriyanto DS, Widodo I, Hakimi M, Hardianti MS, Aryandono T, Haryana SM   +6 more
doaj  

Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. [PDF]

, 2017
In this issue of Cancer Cell, Hydbring and colleagues define a novel class of microRNAs (miRNAs), deemed cell-cycle-targeting miRNAs, that target several cyclins/CDKs, reduce tumor cell growth, and induce apoptosis.
Knudsen, Karen E., Schiewer, Matthew J.
core   +2 more sources

Targeting the Host in TNBC

Annals of Oncology, 2012
ABSTRACT Cancer medicine is increasingly moving toward a new era of personalized therapeutics that embraces integrative approaches. Combinatorial strategies will target not only cancer cell-intrinsic pathways, but also cancer cell-extrinsic cells, pathways, and mediators of the tumor microenvironment.
openaire   +1 more source

Hierarchical Targeting of TREM2+ Myeloid Cells via Acid‐Triggered OMVs Reprogram Immunosuppression and Suppress Osteolysis in Bone‐Metastatic TNBC

Advanced Science, EarlyView.
This study developed a hierarchical targeting nanoplatform, siTREM2@ETP‐PEOz‐OMVs, against triple‐negative breast cancer (TNBC) bone metastasis. It precisely delivers therapeutic siTREM2 to monocytes/macrophages within the metastatic niche. This intervention dually regulates cell fate: reprogramming immunosuppressive macrophages and inhibiting ...
Fanglu Chen, Yucheng Xue, Xiao Ma, Liang Chen, Zhenxuan Shao, Hangxiang Sun, Haochen Mou, Fangqian Wang, Zilong Li, Yechao Shen, Zhaoming Ye, Xiaohua Yu, Shengdong Wang   +12 more
wiley   +1 more source

Inhibition of triple-negative breast cancer growth via delphinidin-mediated suppression of the JAK2/STAT3/PD-L1 pathway

Food & Nutrition Research
Background: Breast cancer is a leading cause of cancer-related mortality among women globally, with triple-negative breast cancer (TNBC) being particularly aggressive.
Xiaoping Yu, Xiaolong Song, Jiali Yan, Ziting Xiong, Lujie Zheng, Yan Luo, Fengcheng Deng, Yanfeng Zhu   +7 more
doaj   +1 more source

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study [PDF]

, 2019
Background Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. Methods Patients with primary triple
Apolone G., Bianchi G. V., Cazzaniga M. E., Colombo M. P., Cosimo S. D., Crippa F., de Braud F., De Santis M. C., Folli S., Generali D., Gulino A., Mariani L., Moretti A., Nicola M. D., Paolini B., Scaperrotta G., Torri V., Tripodo C., Verde N. L.   +18 more
core   +2 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source